Limits...
Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report.

Noguchi E, Kamio T, Kamio H, Miura H, Tamaki M, Nishizawa M, Aoyama K, Oochi T, Kameoka S - Oncol Lett (2014)

Bottom Line: Breast ultrasonography was performed 10 months after the initial trastuzumab administration and the left axillary lymph node enlargement had reduced in size and severity.As determined by the result of a skin biopsy of this area, the patient was diagnosed with occult breast cancer with cutaneous metastases.At present (34 months following lapatinib monotherapy initiation) no new lesions or severe side-effects have been observed.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery II, Tokyo Women's Medical University, Tokyo 162-8666, Japan.

ABSTRACT
The case of a 72-year-old female who identified a lymph node enlargement in the left axilla is reported in the present study. A lymph node biopsy revealed a metastatic adenocarcinoma of the axillary lymph node. Following various assessments, the patient was diagnosed with occult breast cancer and lymph node metastases, for which treatment was initiated. Trastuzumab monotherapy was administered as the patient was elderly, positive for the hepatitis B virus and exhibited the following immunostaining/immunohistochemical analysis results: Estrogen receptor (ER) negative (-), progesterone receptor (PgR) negative (-) and human epidermal growth factor receptor 2 (HER2) positive (3+). Breast ultrasonography was performed 10 months after the initial trastuzumab administration and the left axillary lymph node enlargement had reduced in size and severity. However, a skin rash (erythema) was observed encompassing the left breast and extending into the axilla. As determined by the result of a skin biopsy of this area, the patient was diagnosed with occult breast cancer with cutaneous metastases. The immunohistochemical analysis results obtained from the skin biopsy were similar to those obtained from the lymph nodes: ER (-), PgR (-) and HER2 (3+). Therefore, the patient was switched from trastuzumab to lapatinib monotherapy. The erythema completely disappeared after two months of treatment. At present (34 months following lapatinib monotherapy initiation) no new lesions or severe side-effects have been observed.

No MeSH data available.


Related in: MedlinePlus

Breast ultrasonography of the axillary lesion. A minimum of 20 irregular masses of dispersed sizes were observed surrounding the suspected metastatic left axillary lymph node. The smallest and greatest diameters observed were 5 and 35 mm, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214420&req=5

f2-ol-08-06-2448: Breast ultrasonography of the axillary lesion. A minimum of 20 irregular masses of dispersed sizes were observed surrounding the suspected metastatic left axillary lymph node. The smallest and greatest diameters observed were 5 and 35 mm, respectively.

Mentions: Upon clinical breast examination, no evidence of skin retraction or nipple dimpling was observed. In addition, there was no apparent evidence of a mass in the mammary gland. However, the breast cancer screening revealed a well-defined 30-mm diameter non-movable mass in the left axillary lymph node. A mammography did not reveal any abnormalities on either side and during breast ultrasonography, no marked tumor lesions were detected in the mammary gland. A suspected metastases (maximum diameter, 35 mm) was observed in a lymph node in the left axilla (Fig. 2) and a minimum of 20 irregular masses of varying sizes were observed in this area. No evidence of metastases was detected in the lymph nodes proximal to the sternum and clavicle fossae.


Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report.

Noguchi E, Kamio T, Kamio H, Miura H, Tamaki M, Nishizawa M, Aoyama K, Oochi T, Kameoka S - Oncol Lett (2014)

Breast ultrasonography of the axillary lesion. A minimum of 20 irregular masses of dispersed sizes were observed surrounding the suspected metastatic left axillary lymph node. The smallest and greatest diameters observed were 5 and 35 mm, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214420&req=5

f2-ol-08-06-2448: Breast ultrasonography of the axillary lesion. A minimum of 20 irregular masses of dispersed sizes were observed surrounding the suspected metastatic left axillary lymph node. The smallest and greatest diameters observed were 5 and 35 mm, respectively.
Mentions: Upon clinical breast examination, no evidence of skin retraction or nipple dimpling was observed. In addition, there was no apparent evidence of a mass in the mammary gland. However, the breast cancer screening revealed a well-defined 30-mm diameter non-movable mass in the left axillary lymph node. A mammography did not reveal any abnormalities on either side and during breast ultrasonography, no marked tumor lesions were detected in the mammary gland. A suspected metastases (maximum diameter, 35 mm) was observed in a lymph node in the left axilla (Fig. 2) and a minimum of 20 irregular masses of varying sizes were observed in this area. No evidence of metastases was detected in the lymph nodes proximal to the sternum and clavicle fossae.

Bottom Line: Breast ultrasonography was performed 10 months after the initial trastuzumab administration and the left axillary lymph node enlargement had reduced in size and severity.As determined by the result of a skin biopsy of this area, the patient was diagnosed with occult breast cancer with cutaneous metastases.At present (34 months following lapatinib monotherapy initiation) no new lesions or severe side-effects have been observed.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery II, Tokyo Women's Medical University, Tokyo 162-8666, Japan.

ABSTRACT
The case of a 72-year-old female who identified a lymph node enlargement in the left axilla is reported in the present study. A lymph node biopsy revealed a metastatic adenocarcinoma of the axillary lymph node. Following various assessments, the patient was diagnosed with occult breast cancer and lymph node metastases, for which treatment was initiated. Trastuzumab monotherapy was administered as the patient was elderly, positive for the hepatitis B virus and exhibited the following immunostaining/immunohistochemical analysis results: Estrogen receptor (ER) negative (-), progesterone receptor (PgR) negative (-) and human epidermal growth factor receptor 2 (HER2) positive (3+). Breast ultrasonography was performed 10 months after the initial trastuzumab administration and the left axillary lymph node enlargement had reduced in size and severity. However, a skin rash (erythema) was observed encompassing the left breast and extending into the axilla. As determined by the result of a skin biopsy of this area, the patient was diagnosed with occult breast cancer with cutaneous metastases. The immunohistochemical analysis results obtained from the skin biopsy were similar to those obtained from the lymph nodes: ER (-), PgR (-) and HER2 (3+). Therefore, the patient was switched from trastuzumab to lapatinib monotherapy. The erythema completely disappeared after two months of treatment. At present (34 months following lapatinib monotherapy initiation) no new lesions or severe side-effects have been observed.

No MeSH data available.


Related in: MedlinePlus